p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer:: A multivariate analysis
p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer:: A multivariate analysis
复制标题
DOI：
10.1016/j.ygyno.2004.12.053
复制
发表时间：
2005-04-01
影响因子：
4.7
通讯作者：
Koyuncuoglu, M
中科院分区：
文献类型：
--
作者：
Dogan, E;Saygili, U;Koyuncuoglu, M
目标。本研究旨在探讨p53和mdm2蛋白表达在上皮性卵巢癌中的预后意义及其与临床病理变量的关系。对82例均质治疗的肿瘤活检标本进行免疫组织化学检测p53和mdm2蛋白的表达。对预后因素进行单因素和多因素分析，并检查与临床病理参数的相关性。分别有54%和33%的病例p53和mdm2呈阳性。P53的表达与浆液型、高分级、细胞学阳性、肿瘤残留及疾病分期有关。Rndm2表达预测化疗敏感性，与肿瘤分级相关，但与其他临床病理指标无关。p53 （P < 0.05）或mdm2 （P < 0.01）阳性肿瘤患者的生存率明显低于p53或mdm2阴性肿瘤患者。p53和mdm2的共表达也与预后不良有关（P < 0.05）。多因素分析显示，FIGO分期、mdm2表达、化疗反应和最佳细胞减量是影响生存的重要独立预后和预测因素。虽然我们的研究结果表明mdm2可以作为上皮性卵巢癌患者的预后指标，但这些结果需要更多更大规模的研究来支持。(c) 2005年Elsevier Inc.出版
Objective. The aim of the study was to investigate the prognostic significance of p53 and mdm2 protein expressions in epithelial ovarian cancer and their relationship with the clinicopathological variables.Methods. Tumor biopsy specimens from 82 patients who were homogenously treated were examined immunohistochemically for expression of p53 and mdm2 proteins. Univariate and multivariate analyses were performed for prognostic factors, and correlations with clinicopathological parameters were examined.Results. Fifty-four percent and 33% of cases stained positive for p53 and mdm2, respectively. p53 expression was associated with serous type, higher grade, positive cytology, residual tumor and stage of the disease. rndm2 expression predicted of chemosensitivity and it was related with higher grade but not with other clinicopathological variables. Significantly poorer survival was seen for those with p53 (P < 0.05) or mdm2 (P < 0.01) positive tumors than those with negative p53 or mdm2 staining. Coexpression of p53 and mdm2 was also related to poor outcome (P < 0.05). Multivariate analysis revealed that FIGO stage, mdm2 expression, response to chemotherapy and optimal cytoreduction were significant independent prognostic and predictive factors of survival.Conclusion. Although our findings showed that mdm2 may be used as a prognostic indicator in patients with epithelial ovarian cancer, these results should be supported by more and larger studies. (c) 2005 Published by Elsevier Inc.